🎥 Dr Isabel Rubio stresses the importance of real-world data to guide breast cancer treatment decisions—especially in areas of debate and de-escalation. More studies are needed:
➡️https://buff.ly/JtVsE7J⬅️
#SGBCC2025 #BreastCancer #BCSM
🎥@marleenkok.bsky.social from @nkinl.bsky.social highlights the need for biomarkers to personalize treatment for #TNBC treated with pembrolizumab:
➡️https://buff.ly/DfT8idO⬅️
#SGBCC2025 #BreastCancer #BCSM #ImmunoOnc
ER+/HER2- early #breastcancer: Current & future Tx strategies
📺 Profs. Gnant & Curigliano share an update from #SGBCC2025
See more + get the slides
👉 cor2ed.com/n-connect/pr...
This programme has been sponsored by Menarini Stemline and is intended for healthcare professionals only
#MedEd
Insights from SGBCC 2025 on HER2+ early-stage breast cancer treatment decisions - Aleix Prat
@prat-aleix-md.bsky.social
oncodaily.com/blog/aleix-p...
#Cancer #CancerResearch #Medicine #Health #BreastCancer #SGBCC2025 #Oncology #OncoDaily
💡Paolo Tarantino from Dana-Farber Cancer Institute shared valuable insights from SGBCC 2025.
oncodaily.com/blog/sgbcc-2...
#Cancer #BreastCancer #SGBCC2025 #PrecisionMedicine #TargetedTherapies #BCSM #Medicine #Health #Oncology #OncoDaily
Looking to include more advocate partners in your work, or train as an advocate yourself? @TanjaSpanic @EuropaDonnaSLO includes this list of for places to start. #SGBCC2025
Such a great session on clinical trial design at #SGBCC2025. Importance of patient voice from study design to approval.
Very good talk by famous statistician #SGBCC2025
Meredith Regan proposes framework using established criteria for pragmatic clinical trial design, then walks audience thru process using PREPEC. #masterclass #SGBCC2025
It was great to catch up with Marleen Kok (@marleenkok.bsky.social) on #immunotherapy for ER+ #breastcancer and TNBC, and more at #SGBCC2025!
See who else we've been talking to on VJOncology.com to keep up to date on the latest in breast cancer 🖥️
#bcsm
Delighted to be in Vienna with @CUH/UCC Cancer Centre @cancerresearch-ucc.bsky.com teams
#SGBCC2025
Excited to hear about latest updates in breast cancer care & research!
Christian Singer presents alternatives to bilateral mastectomy for risk reduction in women with BRCA pathogenic variant.
He cites benefits to effective screening (MRI), BSO, tamoxifen, and lifestyle modifications (specifically exercise & weight loss) as strategies.
#SGBCC2025 #brca
Thanks @drsgraff.bsky.social for your amazing report of -again- an amzing session #SGBCC2025
Beyond ChatGPT and digital pathology algorithms, @jnkt.bsky.social reviews current and future states for deep learning artificial intelligence in breast oncology #SGBCC2025
Tanja Spanic
We had the opportunity to catch up with @tanjaspanic.bsky.social at #SGBCC2025, where she talked on tailoring therapies for early #breastcancer, and importance of survivorship and patient advocacy!
Visit VJOncology.com for exclusive interviews and more!
#bcsm
Marleen Kok @marleenkok.bsky.social had the difficult task of discussing the role of IO in HR+ breast cancer—she focused on ER-low disease, and suggests that we treat as TNBC. #SGBCC2025
Fantastic talk answering the question “Which tumors warrant adjuvant CDK4/6 inhibitors?”
Here are the 🔑 take aways from @AngieDemichele (which I was really thankful for, as I otherwise took photos of every slide 😅) #SGBCC2025
Pru Francis says that determining ET options for premenopausal women with breast cancer is the hardest decision we make in medical oncology.
#SGBCC2025
After reviewing the data, @kalinskykevin.bsky.social just cuts to the chase and answers the question—which ER+ tumors still require chemotherapy #SGBCC2025
David Cameron offers cautious approach to implementing CDK4/6 inhibitors after starting w historic perspective that concerns thrown at adjuvant tamoxifen & adjAI are the same concerns voiced today for CDK4/6i. Ends with “Fools rush in where angels fear to tread” #SGBCC2025
🗳️Ultimately, the audience at #SGBCC2025 votes AGAINST (52% vs 46%) radiation for all patients with node-positive breast cancer and low volume nodal disease
On another great day for #HER2DX at St. Gallen Breast Cancer Conference, Dr. #MafaldaOliveira from #SOLTI discusses the DEFINITIVE trial, the first prospective #HER2DX trial across 44 hospitals in 7 countries.
#SGBCC2025
#breastcancer
#precisiononcology
While discussing the PROs RE: mastectomy vs. breast conserving surgery, Jana de Boniface highlights how deeply the degree of patient engagement and choice impact the satisfaction with outcome—which is often an unmeasured variable. #SGBCC2025
Daniela Kauer-Dorner masterfully reviews the data around tailored options for radiotherapy as well as ongoing trials to further resolve questions in the field. #SGBCC2025
Dr. Mafalda Oliveira had the challenge of answering “Pyrrhic victory? Are newer approaches causing more harm than good?” and rose to the challenge, addressing the toxicity and long-lasting impacts of therapy. #SGBCC2025
Issuing a call to action for incorporation of biomarkers in clinical trial design, Mafalda Oliveira speaks to the value of stakeholder engagement in trial design. #SGBCC2025
Focusing on patients at a low risk (emphasis mine) of recurrence, Charlotte Coles reviews the options to optimize therapy.
⚖️ Lots of mix-and-match options that should lend to divergence or freedom of choice on the final consensus panel. #SGBCC2025
For those following along at home—a fantastic interdisciplinary lineup on the schedule today. ☢️🔪💊🤖🩻 #SGBCC2025 #oncsky #bcsm
HER2DX is the test on everyone’s lips, here from Nadia Harbeck slides. Hoping to see Master of Ceremonies @drhburstein.bsky.social grill down during consensus—is it ready for prime time? In which HER2+ populations? If not, what data is needed to flip the switch? #SGBCC2025
